{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T04:33:25Z","timestamp":1686371605072},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A relative wealth of new therapies for acute myeloid leukemia (AML) have led to a rapid shift in treatment paradigms for this disease. Understanding whom, when, and how to treat is more complex than ever before. Here we explore whom to treat with these available new therapies, focusing on special patient populations that include older adults, those with relapsed disease, and those with TP53-mutated AML. These high-risk subgroups are some of the most challenging to care for, but novel treatments are providing them with new hope.<\/jats:p>","DOI":"10.1182\/hematology.2021000228","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:10:45Z","timestamp":1639138245000},"page":"24-29","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Whom should we treat with novel agents? Specific indications for specific and challenging populations"],"prefix":"10.1182","volume":"2021","author":[{"given":"Lindsay","family":"Wilde","sequence":"first","affiliation":[{"name":"Medical Oncology, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Kasner","sequence":"additional","affiliation":[{"name":"Medical Oncology, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"2021121012064536800_hem2021000228C1","unstructured":"National Cancer Institute. SEER preliminary cancer incidence rate estimates for 2017, and diagnosis years 2000 to 2017. Accessed 2019. https:\/\/seer.cancer.gov\/statistics\/preliminary-estimates\/."},{"key":"2021121012064536800_hem2021000228C2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"key":"2021121012064536800_hem2021000228C3","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1186\/s12885-015-1857-x","article-title":"The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma\u2014a Swedish population-based study","volume":"15","author":"Mohammadi","year":"2015","journal-title":"BMC Cancer"},{"issue":"9","key":"2021121012064536800_hem2021000228C4","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"2021121012064536800_hem2021000228C5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/EDBK_239097","article-title":"More versus less therapy for older adults with acute myeloid leukemia: new perspectives on an old debate","volume":"39","author":"Klepin","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"2021121012064536800_hem2021000228C6","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41409-018-0164-y","article-title":"Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia","volume":"53","author":"Bhatt","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2021121012064536800_hem2021000228C7","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B","volume":"108","author":"Fr\u00f6hling","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2021121012064536800_hem2021000228C8","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3324\/haematol.2018.191536","article-title":"Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older","volume":"103","author":"Prassek","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"2021121012064536800_hem2021000228C9","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","article-title":"Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"34","author":"Herold","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"2021121012064536800_hem2021000228C10","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study","volume":"89","author":"Leith","year":"1997","journal-title":"Blood"},{"issue":"7","key":"2021121012064536800_hem2021000228C11","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"issue":"9","key":"2021121012064536800_hem2021000228C12","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"issue":"15","key":"2021121012064536800_hem2021000228C13","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2021121012064536800_hem2021000228C14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2021121012064536800_hem2021000228C15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-134736","article-title":"Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with IDH 1\/2 mutations","volume":"136","author":"Pollyea","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2021121012064536800_hem2021000228C16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2021121012064536800_hem2021000228C17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"suppl 15","key":"2021121012064536800_hem2021000228C18","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1200\/JCO.2020.38.15_suppl.7509","article-title":"Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and 4-year overall survival (OS) follow-up","volume":"38","author":"Hueser","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021121012064536800_hem2021000228C19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.12659\/AOT.915381","article-title":"Outcome and prognostic factors of high-risk acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Zhu","year":"2019","journal-title":"Ann Transplant"},{"issue":"suppl 1","key":"2021121012064536800_hem2021000228C20","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1182\/blood-2018-99-111839","article-title":"The real-world incidence of relapse in acute myeloid leukemia (AML): a systematic literature review (SLR)","volume":"132","author":"Oliva","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2021121012064536800_hem2021000228C21","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.25162","article-title":"Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience","volume":"93","author":"Ganzel","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"2021121012064536800_hem2021000228C22","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Abhishek","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"2021121012064536800_hem2021000228C23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/gcc.22806","article-title":"Clonal evolution of acute myeloid leukemia from diagnosis to relapse","volume":"58","author":"Vosberg","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"issue":"18","key":"2021121012064536800_hem2021000228C24","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2021121012064536800_hem2021000228C25","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1182\/blood-2019-127416","article-title":"Venetoclax in combination with gilteritinib in patients with relapsed\/refractory acute myeloid leukemia: a phase 1b study","volume":"134","author":"Perl","year":"2019","journal-title":"Blood"},{"issue":"25","key":"2021121012064536800_hem2021000228C26","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2021121012064536800_hem2021000228C27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"2021121012064536800_hem2021000228C28","article-title":"Bristol Meyers Squibb provides update on phase 3 IDHENTIFY trial in patients with relapsed or refractory acute myeloid leukemia","author":"Bristol Meyers Squibb","year":"2020"},{"issue":"11","key":"2021121012064536800_hem2021000228C29","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood.V110.11.1857.1857","article-title":"Outcome of relapsed AML patients aged between 50 and 70: the ALFA group experience (ALFA 9801 study)","volume":"110","author":"Merabet","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2021121012064536800_hem2021000228C30","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"issue":"23","key":"2021121012064536800_hem2021000228C31","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"2021121012064536800_hem2021000228C32","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"2021121012064536800_hem2021000228C33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41409-020-01016-9","article-title":"Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT","volume":"56","author":"Najima","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"2021121012064536800_hem2021000228C34","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood-2018-99-117772","article-title":"TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia","volume":"132","author":"Goldberg","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012064536800_hem2021000228C35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2020-142891","article-title":"Treatment with CPX-351 induces deep responses and TP53 mutation clearance in patients with t-AML and AML MRC, including younger patients and those with pre-existing MPNs: a real-world experience","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012064536800_hem2021000228C36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-140182","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with venetoclax and decitabine","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012064536800_hem2021000228C37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-134300","article-title":"Interim analysis of the phase 1b\/2 study of the BCL-2 inhibitor venetoclax in combination with standard intensive AML induction\/consolidation therapy with FLAG-IDA in patients with newly diagnosed or relapsed\/refractory AML","volume":"136","author":"Lachowiez","year":"2020","journal-title":"Blood"},{"key":"2021121012064536800_hem2021000228C38","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies","volume":"9","author":"Chao","year":"2019","journal-title":"Front Oncol"},{"issue":"suppl 1","key":"2021121012064536800_hem2021000228C39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2019-126271","article-title":"The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: phase 1b results","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2021121012064536800_hem2021000228C40","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3324\/haematol.2020.249060","article-title":"To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia","volume":"105","author":"Sallman","year":"2020","journal-title":"Haematologica"},{"issue":"14","key":"2021121012064536800_hem2021000228C41","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"2021121012064536800_hem2021000228C42","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe francophone des my\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/24\/1851553\/24wilde.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/24\/1851553\/24wilde.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:11:14Z","timestamp":1639138274000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/24\/482981\/Whom-should-we-treat-with-novel-agents-Specific"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000228","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}